Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche insists Perjeta combo shows OS advantage in metastatic breast cancer

This article was originally published in Scrip

Executive Summary

Roche/Genentech has said it has encouraging data on overall survival in HER2-positive metastatic breast cancer for the combination of its two HER2 targeted antibodies, Perjeta (pertuzumab) and Herceptin. The antibody combination apparently gave better overall survival in the CLEOPATRA study than Herceptin, when both regimes were used with a background of docetaxel chemotherapy. However, the magnitude of the overall survival advantage is unclear and may not be known until the data appear are presented at a medical meeting.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts